Mupirocin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Using the report template above directly (no additional skill needed — this is a structured content-generation task matching the loaded system prompt).
Note on candidate selection: This evidence pack contains 10 predicted indications ranked by raw TxGNN score. predicted_indications[0] (pleural empyema) has zero supporting evidence and its own rationale states mupirocin cannot reach therapeutic concentration there — reporting it as the lead candidate would be clinically misleading. I’ve instead led with rank 9, Staphylococcal Scalded Skin Syndrome (SSSS), the only candidate reaching evidence stage S2/L3 with a coherent mechanism. The other 9 candidates are summarized briefly at the end for completeness.
Mupirocin: From Topical Skin Infections to Staphylococcal Scalded Skin Syndrome
One-Sentence Summary
Mupirocin is a topical antibacterial agent used for skin infections (e.g., impetigo) and nasal Staphylococcus aureus decolonization; detailed original-indication and mechanism-of-action data were not available in this evidence pack. The TxGNN model predicts potential utility as an adjunct in Staphylococcal Scalded Skin Syndrome (SSSS), a toxin-mediated S. aureus skin disease, supported by 14 publications (no dedicated clinical trials). Mupirocin is currently not marketed in South Africa (0 SAHPRA registrations), and safety/PI data are a Blocking data gap, so this remains a research-stage signal rather than a practice-ready finding.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in South African regulatory data (data gap); generally known as a topical antibacterial for skin infections and nasal S. aureus decolonization |
| Predicted New Indication | Staphylococcal Scalded Skin Syndrome (SSSS) |
| TxGNN Prediction Score | 95.57% (rank 16,549 of all drug-disease pairs) |
| Evidence Level | L3 (observational/cohort studies, no completed RCT) |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data was not available in this evidence pack (data gap). Based on known pharmacology, mupirocin inhibits bacterial isoleucyl-tRNA synthetase, giving it potent activity against Staphylococcus aureus, including MRSA — the same organism responsible for SSSS.
SSSS is caused by exfoliative-toxin-producing strains of S. aureus, most often in neonates and young children. It is not a new disease class for mupirocin so much as a different clinical setting for the same target organism: rather than treating localized impetigo or decolonizing the nares, mupirocin here is used as a topical adjunct alongside systemic antibiotics, or for outbreak-control decolonization of affected/colonized patients and contacts.
This mechanistic continuity — same pathogen, same drug target, different clinical presentation of the toxin-mediated disease spectrum — is why multiple case series and cohort studies (summarized below) describe mupirocin ointment being used alongside IV antibiotics in SSSS management and in neonatal-unit outbreak control, even though no randomized trial has tested it as a standalone SSSS therapy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37404367 | 2023 | Cohort | Clinical, Cosmetic and Investigational Dermatology | Compared outcomes of different IV antibiotics combined with 2% mupirocin ointment in pediatric SSSS — most directly on-topic study |
| 15482208 | 2004 | Review/Cohort | Expert Review of Anti-infective Therapy | Reviews treatment of bullous impetigo and SSSS in infants |
| 8435912 | 1993 | Review | Dermatologic Clinics | Reviews staphylococcal skin disease control, notes topical mupirocin as a valuable addition |
| 16218885 | 2005 | Review | Expert Opinion on Pharmacotherapy | Reviews treatment options for impetigo/staphylococcal skin infection in children |
| 19000857 | 2008 | Review | Archives de Pédiatrie | Reviews management of pediatric skin and soft tissue infections including topical treatment role |
| 16009455 | 2005 | Cohort (outbreak investigation) | Journal of Hospital Infection | Nosocomial SSSS outbreak in 13 neonates; epidemiological investigation and infection-control response |
| 31725120 | 2020 | Cohort | Pediatric Infectious Disease Journal | Molecular epidemiology of ST121 S. aureus clone causing rising SSSS cases in Houston children |
| 9576389 | 1998 | Cohort | Pediatric Infectious Disease Journal | Molecular epidemiology and infection-control strategies for SSSS in premature infants |
| 35358031 | 2022 | Cohort | Journal of Medical Microbiology | Molecular epidemiology and antibiotic resistance of S. aureus (incl. SSSS-related) isolates in hospitalized children |
| 35901469 | 2022 | Case Series | Advances in Neonatal Care | Case series on SSSS identification and wound care in neonates |
Note: Two publications specifically flag emerging mupirocin-resistant S. aureus clones associated with SSSS/skin infection outbreaks (28592549, 30418106) — relevant to antimicrobial stewardship if this indication is pursued further.
South Africa Market Information
Mupirocin currently has no SAHPRA registrations and is not marketed in South Africa according to this evidence pack (0 licenses on file).
Safety Considerations
Key Warnings: Not available — this is a Blocking data gap (TFDA/SAHPRA Professional Information has not been sourced), which prevents a formal S1 safety pre-assessment.
Please refer to the SAHPRA-approved Professional Information (PI) for safety information once available. Report adverse drug reactions to SAHPRA.
Other Candidates Screened (Not Recommended)
The remaining 9 TxGNN-predicted indications in this evidence pack were also screened and are not recommended to progress — most have no clinical trial or literature evidence at all (L5, Hold), and several are explicitly flagged in their own rationale as mechanistically implausible (e.g., pleural empyema — topical mupirocin cannot reach therapeutic pleural concentrations; leukoplakia of vagina — non-infectious disease; “non-human animal disease” — a knowledge-graph labeling artifact, not a real indication). Two others (cutaneous candidiasis, bacterial vaginosis) reached only L4/S1 “Research Question” status due to single case reports with pathogen mismatches (antifungal vs. antibacterial; MRSA vaginitis vs. typical polymicrobial BV).
Conclusion and Next Steps
Decision: Hold
Rationale:
- The SSSS candidate has a coherent mechanism and the best evidence in this pack (L3, cohort-level literature), but rests entirely on observational data with no dedicated RCT.
- Mupirocin is not currently registered or marketed in South Africa, and the safety/PI data gap is rated Blocking — a formal safety pre-assessment (S1) cannot be completed without it.
To proceed, the following is needed:
- SAHPRA/TFDA-sourced Professional Information (warnings, contraindications, DDI) to resolve the Blocking data gap
- Confirmed mechanism-of-action documentation from DrugBank
- A regulatory pathway assessment for an unmarketed drug (e.g., named-patient or compassionate-use access) if clinical use for SSSS is to be considered
- Ideally, a prospective or comparative study of topical mupirocin as SSSS adjunct therapy, given current evidence is limited to cohorts and case series
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.